Cost of subcutaneous immunotherapy in a large insured population in the United States
Authors:
- 12 September 2018
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (2) , 351-358
Abstract
Objective: Allergic rhinitis (AR) affects up to 40% of the United States population, with approximately $11 billion annual medical costs. Allergy immunotherapy is the best option for long-term symptomatic relief, but treatment compliance can be low. The objective was to describe subcutaneous immunotherapy (SCIT)-related costs for patients overall and those with inconsistent treatment. Methods: This study observed commercial and Medicare Advantage with Part D health plan enrollees. Included subjects had claims with AR diagnostic codes during 1 January 2011–31 December 2015 and ≥1 SCIT claim during 1 January 2013–31 December 2015 (index date = first SCIT claim date). A control sample was chosen randomly at a 1:3 ratio of SCIT to controls. Inconsistent use was defined as a ≥90 day gap after ≥1 SCIT. Patient characteristics were compared between SCIT patients and controls. Costs were calculated for all SCIT patients and the inconsistent subgroup. Results: Compared with controls (n = 394,479), SCIT (n = 131,493) patients were younger (39.3 vs. 41.4 years), more likely female (56.4% vs. 50.7%) and more likely in a commercial plan (91.6% vs. 83.6%); all p < .001. Among SCIT patients, 15.1% had inconsistent use. Among all SCIT patients, the 3 year total plan-paid SCIT-related costs were $205,741,125 (18% was for inconsistent subgroup) and patient-paid costs were $47,560,450 (15% for inconsistent). Per-member-per-month costs were $0.48 plan-paid and $0.11 patient-paid, with $0.09 plan-paid and $0.02 patient-paid for inconsistent use. Conclusions: This study showed 15% of patients may have costly inconsistent SCIT treatment. Greater understanding is needed regarding the reasons for inconsistent use of subcutaneous allergy immunotherapy.Keywords
This publication has 21 references indexed in Scilit:
- Allergy Immunotherapy Significantly Reduces Outpatient Services Use For Allergy and Respiratory Conditions In Patients With Newly-Diagnosed Allergic RhinitisJournal of Allergy and Clinical Immunology, 2014
- A retrospective review of veterans' adherence to allergen immunotherapy over 10 yearsAnnals of Allergy, Asthma & Immunology, 2014
- Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapyJournal of Allergy and Clinical Immunology, 2013
- Association of Patient-Centered Outcomes With Patient-Reported and ICD-9-Based Morbidity MeasuresThe Annals of Family Medicine, 2012
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodiesJournal of Allergy and Clinical Immunology, 2011
- Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT studyAllergy, 2007
- Twelve‐year follow‐up after discontinuation of preseasonal grass pollen immunotherapy in childhoodAllergy, 2006
- Long-Term Clinical Efficacy of Grass-Pollen ImmunotherapyNew England Journal of Medicine, 1999
- Patient dropouts before completion of optimal dose, multiple allergen immunotherapyAnnals of Allergy, Asthma & Immunology, 1999